Advertisement

Hypoactivity of rat detrusor muscle in a model of cystitis: exacerbation by non-selective COX inhibitors and amelioration by a selective DP1 receptor antagonist

  • Wesam Bassiouni
  • Tahia Daabees
  • Xavier Norel
  • Amira M. Senbel
Original Article
  • 53 Downloads

Abstract

Various studies have confirmed that prostaglandins (PG) alter the bladder motor activity and micturition reflex in both human and animals. However, no sufficient data is reported about the effect of cyclooxygenase (COX) inhibitors neither in normal bladder physiology nor in pathological conditions. This study aims to compare the potential effects of some COX inhibitors with varying COX-1/COX-2 selectivities (indomethacin, ketoprofen, and diclofenac) with that of the selective COX-2 inhibitor (DFU) on bladder function. The role played by some PGs and their receptors in controlling detrusor muscle function in normal condition and in cystitis is also studied. Organ bath experiments were performed using isolated rat detrusor muscle. Direct and neurogenic contractions were induced using ACh and electric stimulation (EFS), respectively. A model of hemorrhagic cystitis was induced by single injection of cyclophosphamide (300 mg/kg) in rats, and confirmed by histophathological examination. Results are expressed as mean ± SEM of 5–9 rats. Alprostadil and iloprost (1 nM- 10 µM) concentration-dependently potentiated ACh (100 μM)- and EFS (4 Hz)-induced contraction, with maximum potentiation of 40.01 ± 5.29 and 27.59 ± 6.64%, respectively, in case of ACh contractions. In contrast, ONO-AE1-259 (selective EP2 agonist, 1 nM–10 μM) inhibited muscle contraction. SC51322 (EP1-antagonist, 10 μM) and RO1138452 (IP antagonist, 10 μM) inhibited both direct and neurogenic responses. Hemorrhagic cystitis reduced both ACh and EFS responses as well as the potentiatory effect of iloprost and the inhibitory effect of RO1138452 on ACh contractions. ONO-AE3-237 (DP1 antagonist, 1 μM) significantly potentiated contractions in cystitis but showed no effect in normal bladder. A significant inhibition of contractile response was observed in presence of indomethacin, ketoprofen, and diclofenac at all tested concentrations (20, 50, and 100 μM). Highest effect was induced by diclofenac. The effect of these COX inhibitors on EFS contractions was intensified in case of cystitis, indomethacin being the most potent. Atropine (1 nM) significantly reduced indomethacin effect on ACh contraction only in normal rats. On the other hand, DFU (10−6 M) significantly potentiated the contractile effect of ACh in case of cystitis although it showed no effect in normal rats. EP1 receptors seem to play an important role in rat bladder contractility. DP1 receptors as COX-2, on the other hand, gain an important role only in case of cystitis. The use of non-selective COX inhibitors in cystitis may be associated with bladder hypoactivity; selective COX-2 inhibitors may be a safer option.

Keywords

COX inhibitors Cystitis Detrusor muscle Prostanoid 

Notes

Acknowledgements

We thank Prof. Mona Yehia, Ph.D., Professor and Head of the Department of Histochemistry and Cell Biology, Medical Health Institute, Alexandria University, Egypt, for her help in conducting histological studies. We also thank Dr. Takayuki Maruyama for providing the ONO compounds as a gift to Dr. Xavier Norel.

Authors’ contribution

AS and TD conceived the idea. AS, XN, and TD designed research. WB conducted experiments. AS and WB analyzed and interpreted data. AS, WB, and TD revised data and wrote the manuscript. AS and XN were Egyptian and French PI of the project, respectively. All authors read and approved the manuscript.

Funding information

Part of this work was supported by Institue Francais en Egypte, French Agency for the Development of Higher Education and Research, and the Academy of Scientific Research and Technology in Egypt under the frame of “Imhotep Project N°: 31681XL” and “STDF/IFE Project N° 30630”.

Supplementary material

210_2018_1599_MOESM1_ESM.docx (3.6 mb)
ESM 1 (DOCX 3.62 MB)

References

  1. Anderson KE (1993) Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 45(3):253–308Google Scholar
  2. Andersson KE (2016) Potential future pharmacological treatment of bladder dysfunction. Basic Clin Pharmacol Toxicol 119(Suppl 3):75–85Google Scholar
  3. Andersson KE, Arner A (2004) Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 84(3):935–986Google Scholar
  4. Aronsson P, Vesela R, Johnsson M (2014) Inhibition of nitric oxide synthase prevents muscarinic and purinergic functional changes and development of cyclophosphamide-induced cystitis in the rat. Biomed Res Int 2014:359179Google Scholar
  5. Aschan J, Carlens S, Hagglund H, Klaesson S, Mattsson J, Remberger M (1999) Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up. Clin Transpl 13(6):512–519Google Scholar
  6. Badawi JK, Seja T, Bross S (2008) In vitro effects of the cyclooxygenase inhibitor indomethacin and of the phospholipase-C inhibitor U-73122 on carbachol-induced contractions of porcine detrusor muscle. Fundam Clin Pharmacol 22(6):667–672Google Scholar
  7. Bley KR, Bhattacharya A, Daniels DV, Gever J, Jahangir A, O'Yang C, Smith S, Srinivasan D, Ford AP, Jett MF (2006) RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol 147(3):335–345Google Scholar
  8. Boie Y, Stocco R, Sawyer N, Slipetz DM, Ungrin MD, Neuschafer-Rube F, Puschel GP, Metters KM, Abramovitz M (1997) Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol 340(2–3):227–241Google Scholar
  9. Borda E, Contreras-Ortiz N, Gutnisky R, Gimeno MF (1982) In vitro effect of acetylcholine and bethanechol on the contractions of the human detrusor muscle. Influence of prostaglandins. Arch Int Pharmacodyn Ther 259(1):31–39Google Scholar
  10. Brideau C, Van Staden C, Chan CC (2001) In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res 62(11):1755–1760Google Scholar
  11. Cardozo LD, Stanton SL, Robinson H, Hole D (1980) Evaluation of flurbiprofen in detrusor instability. Br Med J 280(6210):281–282Google Scholar
  12. Coleman RA, Smith WL, Narumiya S (1994) International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46(2):205–229Google Scholar
  13. Cox PJ (1979) Cyclophosphamide cystitis—identification of acrolein as the causative agent. Biochem Pharmacol 28(13):2045–2049Google Scholar
  14. Ding HL, Ryder JW, Stull JT, Kamm KE (2009) Signaling processes for initiating smooth muscle contraction upon neural stimulation. J Biol Chem 284(23):15541–15548Google Scholar
  15. Dobrek L, Baranowska A, Skowron B, Thor PJ (2014) The influence of piroxicam, a non-selective cyclooxygenase inhibitor, on autonomic nervous system activity in experimental cyclophosphamide-induced hemorrhagic cystitis and bladder outlet obstruction in rats. Acta Pol Pharm 71(3):497–507Google Scholar
  16. Giglio D, Ryberg AT, To K, Delbro DS, Tobin G (2005) Altered muscarinic receptor subtype expression and functional responses in cyclophosphamide induced cystitis in rats. Auton Neurosci 122(1–2):9–20Google Scholar
  17. Gray KJ, Engelmann UH, Johnson EH, Fishman IJ (1986) Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy. J Urol 136(2):497–500Google Scholar
  18. Guan NN, Svennersten K, de Verdier PJ, Wiklund NP, Gustafsson LE (2015) Receptors involved in the modulation of guinea pig urinary bladder motility by prostaglandin D2. Br J Pharmacol 172(16):4024–4037Google Scholar
  19. Hegde SS (2006) Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147(Suppl 2):S80–S87Google Scholar
  20. Hu VY, Malley S, Dattilio A, Folsom JB, Zvara P, Vizzard MA (2003) COX-2 and prostanoid expression in micturition pathways after cyclophosphamide-induced cystitis in the rat. Am J Physiol Regul Integr Comp Physiol 284(2):R574–R585Google Scholar
  21. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P (2011) Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 108(7):1132–1138Google Scholar
  22. Jeremy JY, Mikhailidis DP, Dandona P (1984) The rat urinary bladder produces prostacyclin as well as other prostaglandins. Prostaglandins Leukot Med 16(2):235–248Google Scholar
  23. Jeremy JY, Tsang V, Mikhailidis DP, Rogers H, Morgan RJ, Dandona P (1987) Eicosanoid synthesis by human urinary bladder mucosa: pathological implications. Br J Urol 59(1):36–39Google Scholar
  24. Klinger MB, Dattilio A, Vizzard MA (2007) Expression of cyclooxygenase-2 in urinary bladder in rats with cyclophosphamide-induced cystitis. Am J Physiol Regul Integr Comp Physiol 293(2):R677–R685Google Scholar
  25. Kothari HV, Lee WH, Ku EC (1987) An alternate mechanism for regulation of leukotriene production in leukocytes: studies with an anti-inflammatory drug, sodium diclofenac. Biochim Biophys Acta 921(3):502–511Google Scholar
  26. Lecci A, Birder LA, Meini S, Catalioto RM, Tramontana M, Giuliani S, Criscuoli M, Maggi CA (2000) Pharmacological evaluation of the role of cyclooxygenase isoenzymes on the micturition reflex following experimental cystitis in rats. Br J Pharmacol 130(2):331–338Google Scholar
  27. Lee T, Hedlund P, Newgreen D, Andersson KE (2007) Urodynamic effects of a novel EP(1) receptor antagonist in normal rats and rats with bladder outlet obstruction. J Urol 177(4):1562–1567Google Scholar
  28. Leslie CA, Pavlakis AJ, Wheeler JS Jr, Siroky MB, Krane RJ (1984) Release of arachidonate cascade products by the rabbit bladder; neurophysiological significance? J Urol 132(2):376–379Google Scholar
  29. Linares-Fernandez BE, Alfieri AB (2007) Cyclophosphamide induced cystitis: role of nitric oxide synthase, cyclooxygenase-1 and 2, and NK(1) receptors. J Urol 177(4):1531–1536Google Scholar
  30. Luheshi GN, Zar MA (1991) The effect of streptozotocin-induced diabetes on cholinergic motor transmission in the rat urinary bladder. Br J Pharmacol 103(3):1657–1662Google Scholar
  31. Macedo FY, Baltazar F, Almeida PR, Tavora F, Ferreira FV, Schmitt FC, Brito GA, Ribeiro RA (2008) Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats. J Cancer Res Clin Oncol 134(1):19–27Google Scholar
  32. Maggi CA (1992) Prostanoids as local modulators of reflex micturition. Pharmacol Res 25(1):13–20Google Scholar
  33. Maggi CA, Patacchini R, Santicioli P, Giuliani S (1991) Tachykinin antagonists and capsaicin-induced contraction of the rat isolated urinary bladder: evidence for tachykinin-mediated cotransmission. Br J Pharmacol 103(2):1535–1541Google Scholar
  34. Narumiya S, Sugimoto Y, Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79(4):1193–1226Google Scholar
  35. Nile CJ, Gillespie JI (2012) Interactions between cholinergic and prostaglandin signaling elements in the urothelium: role for muscarinic type 2 receptors. Urology 79(1):240.e17–240.e23Google Scholar
  36. Nile CJ, de Vente J, Gillespie JI (2010) Stretch independent regulation of prostaglandin E(2) production within the isolated guinea-pig lamina propria. BJU Int 105(4):540–548Google Scholar
  37. Ohmura M, Kondo A, Saito M (1997) Effects of ethanol on responses of isolated rabbit urinary bladder and urethra. Int J Urol 4(3):295–299Google Scholar
  38. Orie NN, Clapp LH (2011) Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: evidence for Gi/o modulation via EP3 receptors. Eur J Pharmacol 654(3):258–265Google Scholar
  39. Ortiz MI, Granados-Soto V, Castaneda-Hernandez G (2003) The NO-cGMP-K+ channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav 76(1):187–195Google Scholar
  40. Oter S, Korkmaz A, Oztas E, Yildirim I, Topal T, Bilgic H (2004) Inducible nitric oxide synthase inhibition in cyclophosphamide induced hemorrhagic cystitis in rats. Urol Res 32(3):185–189Google Scholar
  41. Palea S, Toson G, Pietra C, Trist DG, Artibani W, Romano O, Corsi M (1998) Pharmacological characterization of thromboxane and prostanoid receptors in human isolated urinary bladder. Br J Pharmacol 124(5):865–872Google Scholar
  42. Papworth J, Colville-Nash P, Alam C, Seed M, Willoughby D (1997) The depletion of substance P by diclofenac in the mouse. Eur J Pharmacol 325(2–3):R1–r2Google Scholar
  43. Rahnama'i MS, van Kerrebroeck PE, de Wachter SG, van Koeveringe GA (2012) The role of prostanoids in urinary bladder physiology. Nat Rev Urol 9(5):283–290Google Scholar
  44. Rahnama'i MS, van Koeveringe GA, van Kerrebroeck PE, de Wachter SG (2013) The effect of indomethacin on the muscarinic induced contractions in the isolated normal guinea pig urinary bladder. BMC Urol 13:8Google Scholar
  45. Rao P, Knaus EE (2008) Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 11(2):81s–110sGoogle Scholar
  46. Selg E, Buccellati C, Andersson M, Rovati GE, Ezinga M, Sala A, Larsson AK, Ambrosio M, Lastbom L, Capra V, Dahlen B, Ryrfeldt A, Folco GC, Dahlen SE (2007) Antagonism of thromboxane receptors by diclofenac and lumiracoxib. Br J Pharmacol 152(8):1185–1195Google Scholar
  47. Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56(3):387–437Google Scholar
  48. Takagi-Matsumoto H, Ng B, Tsukimi Y, Tajimi M (2004) Effects of NSAIDs on bladder function in normal and cystitis rats: a comparison study of aspirin, indomethacin, and ketoprofen. J Pharmacol Sci 95(4):458–465Google Scholar
  49. Tanaka I, Nagase K, Tanase K, Aoki Y, Akino H, Yokoyama O (2011) Modulation of stretch evoked adenosine triphosphate release from bladder epithelium by prostaglandin E(2). J Urol 185(1):341–346Google Scholar
  50. Uchiyama T, Chess-Williams R (2004) Muscarinic receptor subtypes of the bladder and gastrointestinal tract. J Smooth Muscle Res 40(6):237–247Google Scholar
  51. Vesela R, Aronsson P, Tobin G (2011) Functional and morphological examinations of P1A1 purinoceptors in the normal and inflamed urinary bladder of the rat. Auton Neurosci 159(1–2):26–31Google Scholar
  52. Wada N, Matsumoto S, Kita M, Watanabe M, Hashizume K, Kakizaki H (2013) Effect of intrathecal administration of E-series prostaglandin 1 receptor antagonist in a cyclophosphamide-induced cystitis rat model. Int J Urol 20(2):235–240Google Scholar
  53. Whittle BJ, Silverstein AM, Mottola DM, Clapp LH (2012) Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol 84(1):68–75Google Scholar
  54. Yan G, Wang Q, Shi H, Han Y, Ma G, Tang C, Gu Y (2013) Regulation of rat intrapulmonary arterial tone by arachidonic acid and prostaglandin E2 during hypoxia. PLoS One 8(8):e73839Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmacology and Toxicology, Faculty of PharmacyAlexandria UniversityAlexandriaEgypt
  2. 2.Laboratory for Vascular Translational Sciences, INSERM U1148, X. Bichat HospitalUniversity Paris XIIIParisFrance
  3. 3.LVTS, INSERM U1148, CHU X. BichatParis Cedex 18France

Personalised recommendations